Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 M4DmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDNNHEzNjVizszN MnXoNU01KGR? NUH1RW5wTE2VTx?= NIDwWoRmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIITy[YF1dWWwdDD3bZRpKHSjbX;4bYZmdg>? NF;WNVgzPTR7MEO4Ny=>
H1703 M1zpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;4TGR[Oi53IN88US=> NYXmNpRrOS12IHS= M37hd2ROW09? M{\ueIVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv M2O1R|I2PDlyM{iz
HUVECs M4\xeGN6fG:2b4jpZ4l1gSCDc4PhfS=> MmW1NVAxKG6P NWXDcI1COjRiaB?= NXewZlhN[XS2ZX71ZZRmeyC2aHWgZYJzd2ejdHn2[UBm\m[nY4TzJI9nKGOjbInjc5NqdiCxbjDWVmkucW6mdXPl[EBkgXSxdH;4bYNqfHl? M1vFOFI2PDVyMUi2
APRE-19 M4[1UmFxd3C2b4Ppd{BCe3OjeR?= NFnqdm02KM7:TR?= MoXRNlQhcA>? NX24WI9M[WKxbHnzbIV{KE[OWj3t[YRq[XSnZDDwdo8ue3W{dnn2ZYww[W62aT3hdI9xfG:|aYOgZYN1cX[rdIm= MWOyOVMzQTZzNx?=
MDA-MB-231 MkDtRZBweHSxc3nzJGF{e2G7 MW[xxsDPxE4EoB?= MY[0PEBp Mon0SG1UVw>? NYXkUoU2\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKHS{ZXH0[YQhf2m2aDCyOUDPxE1ib3[gSlEhd3JiRkKgxsA> NWD2eZJuOjV|MEC5N|I>
MCF7 Mn;qSpVv[3Srb36gRZN{[Xl? M{fPVVExOCCwTR?= NWTpSohqOjRiaB?= M4LFV4VtcW2rbnH0[ZMhTTJvaX7keYNm\CCDUlWtUJVkKGGldHn2bZR6 MX2yOVE4OjV3Nx?=
HT-29  NIfaRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITs[ZMyNjYEoNM1US=> NYn6PG5HQTZiaB?= M3TYRoRm[3KnYYPld{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWgbY5pcWKrdHXkJIJ6KEu\TlG= NX\lNHlJOjVyMUKxNlM>
MO59K  M3Pob2N6fG:2b4jpZ4l1gSCDc4PhfS=> M{P2dFXDqM7:TR?= NFf4eWE4KGR? M13mb2ROW09? NWniSJJN\W6qYX7j[ZMhfGinIHP5eI91d3irY3n0fUBw\iCndH;wc5Nq\GVib4KgZ4l{eGyjdHnu M1j1NFI1QTV|NU[x
MO59J NFvtO|VEgXSxdH;4bYNqfHliQYPzZZk> MlTDOeKh|ryP NFnIWm44KGR? NH21W4lFVVOR M3\3TIVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= MmL3NlQ6PTN3NkG=
MO59K  NIPFPGhCeG:ydH;zbZMhSXO|YYm= NYXRXGlqOTBizszN MYCyOEBp NF3yRWpFVVOR NFrDcpBqdmO{ZXHz[ZMhfGinIFTTRkBt\X[nbDDpcoR2[2WmIHL5JIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? MlHqNlQ6PTN3NkG=
MO59J NUfqRoxjSXCxcITvd4l{KEG|c3H5 Mon2NVAh|ryP NU\vXGtVOjRiaB?= M3TMUWROW09? MnvzbY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv MV[yOFk2OzV4MR?=
HepG2 MoX5SpVv[3Srb36gRZN{[Xl? Ml;6NVAxKG6P MoTiNE42KGh? NFXCWXRFVVOR NFyybVdjdG:la4OgUWEucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v NFTjUI4zPDh4M{O1NC=>
A549  NF3a[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKzJOK2VcLi NIDwfYQzKGh? MUfzeZBxemW|c3XzJJBmdWW2cnX4[YQucW6mdXPl[EBCc3RiYX7kJGdUUzQQsjDhZ5RqfmG2aX;uMEBUNXCqYYPlJIFzemW|dDygZ4VtdCCjcH;weI9{cXNiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v NV;SfmFkOjR6NEe4OlM>
A549  M4TlXWZ2dmO2aX;uJGF{e2G7 M4Sye|ExyqEQvH5CpC=> M3jzbVE3KGh? MmfSSG1UVw>? NIPqeIpud2S3bHH0[ZMhfGinIFnBWkBz\XCuaXPheIlwdiCjbnSgZ4F2e2W|IILleIVvfGmxbjDv[kBPWCCrbjD0bIUhdnWlbHX1d{4> M2S5OlI1QDB{MUGx
SK-N-LO NGPJSGJHfW6ldHnvckBCe3OjeR?= NGfxfWoyODBibl2= Mn2wNE42KGh? MVvk[YNz\WG|ZYOgeIhmKHO2aX31cIFvfCCnZn\lZ5R{KG:oIH3vdpBpcW6nIH;uJGFsfCCyaH;zdIhwenmuYYTpc44> NXTGUYNLOjR4NUS2NFY>
HL-60 MkHjSpVv[3Srb36gRZN{[Xl? MkniNE4yyqEQvF2= NEPDXWU4OiCq NYHkPHdn[myxY3vzJIRie2G2aX7pZk1qdmS3Y3XkJINmdGxiZHnm[oVz\W62aXH0bY9v NF\LZ3czPDZyN{K3Ny=>
HepG2  M{HxbWZ2dmO2aX;uJGF{e2G7 NULTZWFIOjByIH7N NH[3TpoxNjViaB?= NYHWbHBp[XS2ZX71ZZRmeyCIb4jPJJBpd3OyaH;yfYxifGmxbh?= MXqyOFU{PTF7Mh?=
H520 M13ZWGZ2dmO2aX;uJGF{e2G7 NEDwfYcyOMLizszN M1XmSVEhcA>? Mk[5SG1UVw>? M3;zToRm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> Mor6NlQ1PDd7M{W=
H1975 NWLqcoJuTnWwY4Tpc44hSXO|YYm= NHXtPFMyOMLizszN NXHuSXFrOSCq M{PUcGROW09? NEW0dnRl\WO{ZXHz[ZMh[2WubIXsZZIheGixc4Doc{1CU1RicILveIVqdiCuZY\lcJM> M3Hi[|I1PDR5OUO1
MG-63 Mo\URZBweHSxc3nzJGF{e2G7 MVyxNEDDvU1? NX[0PWN4OTJiaB?= NYLtbXQz\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? NICzTJMzPDN3OEOwNS=>
5637 NGfifmNCeG:ydH;zbZMhSXO|YYm= MUGxNOKh|ryP M3[yb|QxKG2rbh?= M4fTcJJmfmW{c3XzJJAzOVeDRkGg[ZhxemW|c3nvckwhS0SNIHX4dJJme3Orb36sJIFv\CClZXzsJIlvcGmkaYTpc44hcW6mdXPl[EBjgSCodXPvbYRidg>? NX3KXZB5OjR|M{O4Olg>
HEK-293 NUHVXHFTTnWwY4Tpc44hSXO|YYm= NFSx[ZoyPTCwTR?= NF3EU4IyPiCq MVzEUXNQ M3PoUIRm[3KnYYPld{BEWlRiYXP0bZZqfHl? MYmyOFMzPDN4Nh?=
SW480  NVvZ[o9uTnWwY4Tpc44hSXO|YYm= M{XnNlE2OG6P NIPiPY4zOCCq NWrtOY9WTE2VTx?= MU\y[YR2[2W|IHPlcIx2dGG{IHHjZ5VufWyjdHnvckBw\iEQsj3jZZRmdmmw NV3xU3ZMOjR|MkSzOlY>
HepG2 MkPtSpVv[3Srb36gRZN{[Xl? MmTNNVAxKG6P M3Pmd|I1KGh? NWS1cI9U[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= NX;G[nNDOjR{OUe1NVA>
HCT 116  MXrGeY5kfGmxbjDBd5NigQ>? NWPsVGI4OTByIH7N NUT4RldFOjRiaB?= MWjheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? NIC3NFEzPDJ7N{WxNC=>
BEL/FU M4e0XGZ2dmO2aX;uJGF{e2G7 NF:1SFcyKG2P M2\3fVI1KGh? MUjk[YNz\WG|ZYOgdJJwfGWrbjDs[ZZmdHNib3[geIhmKFCLM1uvRYt1KHCjdHj3ZZk> MoTZNlQzOzJyOUm=
Huh7  NXzsO4xxTnWwY4Tpc44hSXO|YYm= MVizxsDPxE1? M3vqPFEhcA>? M{TSSJJm\HWlZYOgeIhmKH[rcoXzJIVvfHK7IHnueI8hfGinIHPlcIx{ MYOyOFE5PDF7Nh?=
A-375 MWXBdI9xfG:|aYOgRZN{[Xl? Mm\GOE85KM7:TR?= M3HBS|I1KGh? NWryUXlV\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MlLtNlQyOTNzN{O=
A-375-TS  M2[x[mFxd3C2b4Ppd{BCe3OjeR?= MWC0M|gh|ryP MknXNlQhcA>? MkLF[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= M2S3WVI1OTF|MUez
Mel-HO NWnsXnNQSXCxcITvd4l{KEG|c3H5 NXe3b5FDPC96IN88US=> MmnzNlQhcA>? NYX3NI9W\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MVKyOFEyOzF5Mx?=
Mel-HO-TS NX\uToxGSXCxcITvd4l{KEG|c3H5 NVrodGdxPC96IN88US=> MXOyOEBp MVTlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MVWyOFEyOzF5Mx?=
MeWo MYnBdI9xfG:|aYOgRZN{[Xl? M3rXcFQwQCEQvF2= M4jjRVI1KGh? NH;QU3NmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NXfQVGdVOjRzMUOxO|M>
Mel-2a M2XtRmFxd3C2b4Ppd{BCe3OjeR?= M4n2cVQwQCEQvF2= NWTBU3JkOjRiaB?= MYflcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MY[yOFEyOzF5Mx?=
MDA-MB-231 MlrISpVv[3Srb36gRZN{[Xl? NV;MNnl3OOLCk{SwNEBvVQ>? NWnXU|BoPCCq M3TSdpN2eHC{ZYPz[ZMhSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYKyNlkxPjJ3OR?=
MDA-MB-231 NF\0c5FHfW6ldHnvckBCe3OjeR?= NUG2b|FmPDByIH7N NIfCUpc1KGh? NXjhXHVG\GWlcnXhd4V{KE2PUD25JIFv\CCLTD24JJBzd3SnaX6gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NH3kXZUzOjlyNkK1PS=>
Jurkat NVXtT49tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rqNVAvOjVvMT6yOUDPxE1? MmDnNlQwPDhiaB?= MoLVSG1UVw>? MUDpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NVHVdI0xOTl5NUexPFU>
Namalwa M4S5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvBTYsxNjJ3LUGuNlUh|ryP NFnjUoozPC92ODDo M{Duc2ROW09? MUPpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? Mm\UNVk4PTdzOEW=
Jurkat MYTBdI9xfG:|aYOgRZN{[Xl? NInme28xNjJ3LUGuNlUh|ryP MWeyOE81QCCq NFfDTIlFVVOR M2rvcYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> Mmn2NVk4PTdzOEW=
Namalwa MVLBdI9xfG:|aYOgRZN{[Xl? MUOwMlI2NTFwMkWg{txO NWLUNIl2OjRxNEigbC=> NFW5TJVFVVOR MWjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= NYPFZY1NOTl5NUexPFU>
K562 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fvdlI1KGh? MmLjTWM2OD1{NdMxNE4yPCCwTR?= NHjrOGUyQTZ4MkO2NS=>
SW1990 MVzGeY5kfGmxbjDBd5NigQ>? NXrJfol1OC5yMT2xJO69VQ>? NF\ZfpUyKGh? NHPsUHdqdmirYnn0d{BJSS2rbnT1Z4VlKEGtdDDwbI9{eGixconsZZRqd25? NV22UJdvOTl2NkmwNlA>
RT112  NET6e2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOxNOKh|ryP NUXGNVdKOjRiaB?= MVvEUXNQ M1zaT4Rm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ NW\6N2ZrOTh5OEe4N|I>
MHG-U1 MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmxNOKh|ryP MnS2NlQhcA>? M1nFSmROW09? NHywbWxl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? NVjTOpVNOTh5OEe4N|I>
SMMC-7721 MnKzRZBweHSxc3nzJGF{e2G7 NYTQWFduOjBywrDuUS=> NFWxVG0zPCCq NWruXmNxcW6lcnXhd4V{KEOKWD3pcoR2[2WmIHHwc5B1d3Orcx?= NXfnOGRxOTd3NUexPVE>
SMMC-7721 NF\MT4FHfW6ldHnvckBCe3OjeR?= NX3TNphEOjBywrDuUS=> MUWyOEBp M{j6dJVxNXKnZ4XsZZRmeyEQskGsOGdVOSCneIDy[ZN{cW:w NUjEOGcxOTd3NUexPVE>
HeLa MVjGeY5kfGmxbjDBd5NigQ>? M4TpWFExOMLibl5CpC=> NEjlXXIyKGh? MVHhcJRmenNidHjlJI1wenCqb3zv[5khd2ZidHjlJJRz[W6|ZnXydolvKHKnY4njcIlv\yClb33wZZJ1dWWwdB?= M4raOlE3QDlyOUG1
MRC5VI NHnHeYZHfW6ldHnvckBCe3OjeR?= NV6xfphsOTJwNTDtUS=> NF7reXcxNjViaB?= MWTEUXNQ M33ubYFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh Mn;mNVYzOjd|OUS=
AT5BIVA NXzTNlVoTnWwY4Tpc44hSXO|YYm= NGnTeXYyOi53IH3N MkHmNE42KGh? MU\EUXNQ NYX0eFZ6[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? MlvLNVYzOjd|OUS=
M059J MnuySpVv[3Srb36gRZN{[Xl? NF\M[IwyOi53IH3N NWPUeWJQOC53IHi= NFnoZYFFVVOR M{T2R4Fjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NXnCUmJbOTZ{MkezPVQ>
HeLa NV\QcXRsTnWwY4Tpc44hSXO|YYm= NV7EZYhEOTJwNTDtUS=> NIH0SGgxNjViaB?= NV:wS4tsTE2VTx?= NHO1b5hi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? NH\nPWUyPjJ{N{O5OC=>
N2a Mn\LRZBweHSxc3nzJGF{e2G7 Mo\4NE4yNTFyIN88US=> Mk\QNkBp MVjpcoR2[2W|IHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? M{LjPVE2QDR{N{[3
Jurkat  NHHIe5BMcW6jc3WgRZN{[Xl? NYCzWIhNUUN3MDDv[kAzPCCwTR?= MYGxOVY3PDVzOR?=

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+corn oil
For best results, use promptly after mixing.
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID